Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Current Assets (2019 - 2025)

IDEAYA Biosciences' Current Assets history spans 7 years, with the latest figure at $666.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 3.33% year-over-year to $666.7 million; the TTM value through Dec 2025 reached $666.7 million, down 3.33%, while the annual FY2025 figure was $666.7 million, 3.33% down from the prior year.
  • Current Assets for Q4 2025 was $666.7 million at IDEAYA Biosciences, down from $802.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $932.2 million in Q3 2024 and bottomed at $251.0 million in Q4 2021.
  • The 5-year median for Current Assets is $492.0 million (2023), against an average of $508.4 million.
  • The largest annual shift saw Current Assets surged 244.45% in 2021 before it dropped 16.91% in 2022.
  • A 5-year view of Current Assets shows it stood at $251.0 million in 2021, then soared by 47.59% to $370.5 million in 2022, then soared by 43.78% to $532.6 million in 2023, then rose by 29.49% to $689.7 million in 2024, then decreased by 3.33% to $666.7 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Current Assets are $666.7 million (Q4 2025), $802.7 million (Q3 2025), and $685.6 million (Q2 2025).